Publications dans lesquelles il/elle collabore avec Amaia Erdozain Fernández (15)

2023

  1. Maternal Immune Activation Induces Cortical Catecholaminergic Hypofunction and Cognitive Impairments in Offspring

    Journal of Neuroimmune Pharmacology, Vol. 18, Núm. 3, pp. 348-365

2021

  1. Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment

    European Neuropsychopharmacology, Vol. 42, pp. 12-21

  2. α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects

    European Neuropsychopharmacology, Vol. 52, pp. 3-11

2019

  1. Differential α 2A - and α 2C -adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex

    Journal of Psychopharmacology, Vol. 33, Núm. 2, pp. 244-249

  2. Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons

    Brain Structure and Function, Vol. 224, Núm. 3, pp. 1219-1244

2018

  1. Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 81, pp. 236-242

  2. Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions

    Neuropsychopharmacology, Vol. 43, Núm. 5, pp. 1041-1051

2015

  1. Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects

    Journal of Psychopharmacology, Vol. 29, Núm. 11, pp. 1137-1145

  2. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects

    Addiction Biology, Vol. 20, Núm. 4, pp. 773-783

2014

  1. Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

    Drug Design, Development and Therapy, Vol. 8, pp. 263-277

2012

  1. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain

    Biochemical Pharmacology, Vol. 83, Núm. 2, pp. 260-268

2009

  1. Implicación del sistema cannabinoide endógeno en el alcoholismo

    Trastornos adictivos: Organo Oficial de la Sociedad española de Toxicomanías, Vol. 11, Núm. 2, pp. 85-95

  2. ¿Es realmente el consumo de cannabis un factor de riesgo para la esquizofrenia?

    Norte de Salud Mental, Vol. 8, Núm. 34, pp. 23-33

2008

  1. Guanidine and 2-aminoimidazoline aromatic derivatives as α2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants

    Journal of Medicinal Chemistry, Vol. 51, Núm. 11, pp. 3304-3312

  2. Novel synthesis and pharmacological evaluation as α2-adrenoceptor ligands of O-phenylisouronium salts

    Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 17, pp. 8210-8217